BioLineRx (BLRX) Reports Positive Data from Phase 2a Study of BL-8040
Tweet Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX), announced today that data from the on-going Phase 2a clinical trial of BL-8040 for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
